O	0	8	Efficacy
O	9	11	of
B-intervention	12	17	short
I-intervention	17	18	-
I-intervention	18	22	term
I-intervention	23	36	psychodynamic
I-intervention	37	50	psychotherapy
I-intervention	51	52	(
I-intervention	52	56	STPP
I-intervention	56	57	)
O	58	62	with
O	63	72	depressed
O	73	79	breast
O	80	86	cancer
O	87	95	patients
O	95	96	:
O	97	104	results
O	105	107	of
O	108	109	a
O	110	120	randomized
O	121	131	controlled
O	132	143	multicenter
O	144	149	trial
O	149	150	.

O	151	156	There
O	157	159	is
O	160	161	a
O	162	166	lack
O	167	169	of
O	170	176	trials
O	177	179	of
O	180	193	psychodynamic
O	194	204	treatments
O	205	207	of
O	208	218	depression
O	219	221	in
O	222	228	breast
O	229	235	cancer
O	236	244	patients
O	244	245	.

O	246	249	The
O	250	257	purpose
O	258	260	of
O	261	265	this
O	266	271	trial
O	272	275	was
O	276	278	to
O	279	288	determine
O	289	292	the
O	293	301	efficacy
O	302	304	of
O	305	310	short
O	310	311	-
O	311	315	term
O	316	329	psychodynamic
O	330	343	psychotherapy
O	344	345	(
O	345	349	STPP
O	349	350	)
O	351	353	in
O	354	357	non
O	357	358	-
O	358	368	metastatic
O	369	375	breast
O	376	382	cancer
O	383	391	patients
O	392	401	diagnosed
O	402	406	with
O	407	417	depression
O	417	418	,
O	419	422	one
O	423	425	of
O	426	429	the
O	430	434	most
O	435	443	frequent
O	444	450	mental
O	451	464	comorbidities
O	465	467	of
O	468	474	breast
O	475	481	cancer
O	481	482	.

O	483	485	In
O	486	487	a
O	488	499	multicenter
O	500	511	prospective
O	512	517	trial
O	517	518	,
B-total-participants	519	522	157
B-eligibility	523	529	breast
I-eligibility	530	536	cancer
I-eligibility	537	545	patients
I-eligibility	546	550	with
I-eligibility	551	559	comorbid
I-eligibility	560	570	depression
O	571	575	were
O	576	586	randomized
O	587	589	to
O	590	596	either
O	597	607	individual
O	608	612	STPP
O	613	614	(
O	614	626	intervention
O	627	632	group
O	632	633	,
O	634	635	N
O	635	636	=
B-intervention-participants	636	638	78
O	638	639	)
O	640	642	or
B-control	643	644	'
I-control	644	653	treatment
I-control	654	656	as
I-control	657	662	usual
I-control	662	663	'
O	664	665	(
O	665	672	control
O	673	678	group
O	678	679	,
O	680	683	TAU
O	683	684	,
O	685	686	N
O	686	687	=
B-control-participants	687	689	79
O	689	690	)
O	690	691	.

O	692	694	As
O	695	698	our
O	699	706	primary
O	707	714	outcome
O	715	722	measure
O	722	723	,
O	724	726	we
O	727	739	hypothesized
O	740	741	a
O	742	748	higher
B-outcome-Measure	749	753	rate
I-outcome-Measure	754	756	of
I-outcome-Measure	757	766	remission
O	767	774	defined
O	775	777	as
O	778	780	no
O	781	790	diagnosis
O	791	793	of
O	794	804	depression
O	805	806	(
O	806	816	Structured
O	817	825	Clinical
O	826	835	Interview
O	836	839	for
O	840	843	DSM
O	843	844	-
O	844	846	IV
O	846	847	)
O	848	851	and
O	852	861	reduction
O	862	864	in
O	865	875	depression
O	876	881	score
O	882	884	by
O	885	887	at
O	888	893	least
O	894	895	2
O	896	902	points
O	903	904	(
O	904	912	Hospital
O	913	920	Anxiety
O	921	924	and
O	925	935	Depression
O	936	941	Scale
O	941	942	,
O	943	947	HADS
O	947	948	-
O	948	949	D
O	949	950	)
O	951	953	in
O	954	958	STPP
O	959	965	versus
O	966	969	TAU
O	970	972	at
O	973	982	treatment
O	983	994	termination
O	994	995	.

O	996	1005	Secondary
O	1006	1014	outcomes
O	1015	1021	mainly
O	1022	1027	refer
O	1028	1030	to
B-outcome-Measure	1031	1038	quality
I-outcome-Measure	1039	1041	of
I-outcome-Measure	1042	1046	life
I-outcome-Measure	1047	1048	(
I-outcome-Measure	1048	1051	QoL
I-outcome-Measure	1051	1052	)
O	1052	1053	.

O	1054	1056	In
O	1057	1060	the
O	1061	1070	intention
O	1071	1073	to
O	1074	1079	treat
O	1080	1081	(
O	1081	1084	ITT
O	1084	1085	)
O	1086	1094	analysis
O	1094	1095	,
B-iv-bin-percent	1096	1098	44
I-iv-bin-percent	1098	1099	%
O	1100	1102	of
O	1103	1106	the
O	1107	1111	STPP
O	1112	1117	group
O	1118	1126	achieved
O	1127	1133	highly
O	1134	1147	significantly
O	1148	1152	more
B-outcome	1153	1162	remission
O	1163	1167	than
O	1168	1171	TAU
O	1172	1173	(
B-cv-bin-percent	1173	1175	23
I-cv-bin-percent	1175	1176	%
O	1176	1177	)
O	1177	1178	.

B-outcome	1179	1183	STPP
I-outcome	1184	1193	treatment
O	1194	1195	(
O	1195	1197	OR
O	1197	1198	=
O	1198	1199	7
O	1199	1200	.
O	1200	1202	64
O	1202	1203	;
O	1204	1205	P
O	1205	1206	<
O	1206	1207	0
O	1207	1208	.
O	1208	1211	001
O	1211	1212	)
O	1213	1216	was
O	1217	1220	the
O	1221	1230	strongest
O	1231	1240	predictor
O	1241	1244	for
O	1245	1254	remission
O	1255	1259	post
O	1259	1260	-
O	1260	1269	treatment
O	1269	1270	;
B-outcome	1271	1275	time
O	1276	1279	was
O	1280	1284	also
O	1285	1296	significant
O	1297	1298	(
O	1298	1300	OR
O	1300	1301	=
O	1301	1302	0
O	1302	1303	.
O	1303	1305	96
O	1305	1306	;
O	1307	1308	P
O	1308	1309	<
O	1309	1310	0
O	1310	1311	.
O	1311	1313	05
O	1313	1314	)
O	1314	1315	.

O	1316	1317	A
O	1318	1322	high
O	1323	1329	effect
O	1330	1338	favoring
O	1339	1343	STPP
O	1344	1345	(
O	1345	1346	d
O	1346	1347	=
O	1347	1348	0
O	1348	1349	.
O	1349	1351	82
O	1351	1352	)
O	1353	1356	was
O	1357	1365	observed
O	1366	1369	for
O	1370	1373	the
B-outcome	1374	1378	HADS
I-outcome	1378	1379	-
I-outcome	1379	1380	D
I-outcome	1381	1386	score
I-outcome	1387	1391	post
I-outcome	1391	1392	-
I-outcome	1392	1401	treatment
O	1402	1403	(
O	1403	1412	secondary
O	1413	1420	outcome
O	1420	1421	)
O	1421	1422	.

O	1423	1432	Regarding
O	1433	1440	further
O	1441	1450	secondary
O	1451	1459	outcomes
O	1460	1461	(
B-outcome	1461	1464	QoL
O	1464	1465	)
O	1465	1466	,
O	1467	1475	analyses
O	1476	1478	of
O	1479	1489	covariance
O	1490	1497	yielded
O	1498	1502	main
O	1503	1510	effects
O	1511	1514	for
O	1515	1520	group
O	1521	1522	(
O	1522	1530	favoring
O	1531	1535	STPP
O	1536	1540	with
O	1541	1543	an
O	1544	1550	effect
O	1551	1555	size
O	1556	1558	of
O	1559	1561	at
O	1562	1567	least
O	1568	1569	d
O	1569	1570	=
O	1570	1571	0
O	1571	1572	.
O	1572	1573	5
O	1573	1574	)
O	1575	1578	for
O	1579	1585	global
O	1586	1589	QoL
O	1589	1590	,
O	1591	1595	role
O	1595	1596	,
O	1597	1606	emotional
O	1607	1610	and
O	1611	1617	social
O	1618	1629	functioning
O	1629	1630	,
O	1631	1635	pain
O	1635	1636	,
O	1637	1646	treatment
O	1647	1651	side
O	1651	1652	-
O	1652	1659	effects
O	1659	1660	,
O	1661	1667	breast
O	1668	1676	symptoms
O	1677	1680	and
O	1681	1686	upset
O	1687	1689	by
O	1690	1694	hair
O	1695	1699	loss
O	1699	1700	.

O	1701	1705	STPP
O	1706	1708	is
O	1709	1711	an
O	1712	1721	effective
O	1722	1731	treatment
O	1732	1734	of
O	1735	1736	a
O	1737	1742	broad
O	1743	1748	range
O	1749	1751	of
O	1752	1762	depressive
O	1763	1773	conditions
O	1774	1776	in
O	1777	1783	breast
O	1784	1790	cancer
O	1791	1799	patients
O	1800	1809	improving
O	1810	1820	depression
O	1821	1824	and
O	1825	1835	functional
O	1836	1839	QoL
O	1839	1840	.

O	1841	1849	Findings
O	1850	1853	are
O	1854	1861	limited
O	1862	1864	by
O	1865	1868	the
O	1869	1873	drop
O	1873	1874	-
O	1874	1877	out
O	1878	1882	rate
O	1883	1884	(
O	1884	1885	âˆ¼
O	1885	1886	1
O	1886	1887	/
O	1887	1888	3
O	1888	1889	)
O	1890	1893	and
O	1894	1901	delayed
O	1902	1906	post
O	1906	1907	-
O	1907	1916	treatment
O	1917	1928	assessments
O	1928	1929	.

O	1930	1936	Future
O	1937	1943	trials
O	1944	1947	may
O	1948	1956	consider
O	1957	1964	stepped
O	1964	1965	-
O	1965	1969	care
O	1970	1980	approaches
O	1980	1981	,
O	1982	1990	tailored
O	1991	1993	to
O	1994	2002	patients
O	2002	2003	'
O	2004	2009	needs
O	2010	2013	and
O	2014	2026	requirements
O	2027	2029	in
O	2030	2033	the
O	2034	2039	acute
O	2040	2049	treatment
O	2050	2055	phase
O	2055	2056	.
